BIOSYNTECH, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -.--% |
|
-.--% | -.--% |
| Sales 2008 | 274K 200K 15.98M | Sales 2009 | 40.77K 29.82K 2.38M | Capitalization | 12.01M 8.79M 701M |
|---|---|---|---|---|---|
| Net income 2008 | -9M -6.58M -525M | Net income 2009 | -12M -8.78M -700M | EV / Sales 2008 | 88 x |
| Net Debt 2008 | 240K 175K 13.99M | Net Debt 2009 | 8.28M 6.05M 483M | EV / Sales 2009 | 498 x |
| P/E ratio 2008 |
-2.58
x | P/E ratio 2009 |
-0.93
x | Employees | - |
| Yield 2008 * |
-
| Yield 2009 |
-
| Free-Float | 58.8% |
More Fundamentals
* Assessed data
3 years
0.00
0.01
5 years
0.000.03
10 years
0.000.03
BioSyntech, Inc. is a Canada-based biotechnology company. The Company is developing biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. The Company's platform technology is a family of hydrogels called BST-Gel, some of which are liquid at low temperature and solid at human body temperature. These gels can be injected or applied to a specific local site and offers properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds and provide the benefit of avoiding invasive surgery. The Company's lead, late-stage product, BST-CarGel is undergoing an international pivotal trial.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 116 | |
| +2.41% | 42.75B | |
| +47.64% | 41.61B | |
| +12.02% | 41.34B | |
| -12.36% | 26.59B | |
| +8.42% | 25.49B | |
| -23.35% | 18.12B | |
| +30.52% | 12.24B | |
| -1.56% | 11.76B | |
| +7.86% | 11B |
- Stock Market
- Equities
- BSYI Stock
